Open AccessREMDESIVIR IN THE TREATMENT OF COVID-19: A SHORT OUTLINE
Author(s) -
Pydala Sai Prasanna,
Ragam Swetha Samrajyam,
Kasani Chitti Ramya,
Ambati Sujatha,
Satheesh S. Gottipati,
P. Srinivasbabu
Publication year - 2021
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/13385
Subject(s) - covid-19 , virology , replication (statistics) , prodrug , coronavirus , viral replication , medicine , outbreak , betacoronavirus , clinical trial , pharmacology , virus , infectious disease (medical specialty) , disease
We look at the clinical development of remdesivir, a prodrug that has been shown to inhibit SARS-CoV-2 replication, indicating that it could be used to treat COVID-19. Remdesivir is a nucleotide analogue prodrug that disrupts viral replication and was first tested in clinical trials in 2014 to combat the Ebola outbreak.The ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2, was later demonstrated by numerous virology laboratories. Well go over how remdesivir was discovered, how it works, and what studies are currenty being done to see how effective it is in the clinic.